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osting by EAbstract Several 3-amantadinyl-2-[(2-substituted benzylidenehydrazinyl)methyl]-quinazolin-4(3H)-
ones (5a–5l) were prepared by the reaction of 3-amantadinyl-2-hydrazinylmethyl substituted qui-
nazolin-4(3H)-ones (4a–4b) with various substituted aromatic aldehydes. Cycloaddition of
compounds (5a–5l) with thioglycolic acid in the presence of anhydrous zinc chloride yielded
3-amantadinyl-2-[((substitutedphenyl)-4-oxo-thiazolidin-3-yl)methylamino]-quinazolin-4(3H)-ones
(6a–6l). Compounds 5a–5l on further reaction with chloro acetyl chloride in the presence of trieth-
ylamine gave 3-amantadinyl-2-[((substitutedphenyl)-3-chloro-2-oxo-azetidin-1-yl)methylamino]-
quinazolin-4(3H)-ones (7a–7l). The compounds 5a–5l, 6a–6l and 7a–7l were screened for their
antiparkinsonian activity. The most active compound was 6g i.e. 3-amantadinyl-6-bromo-2-
[((3,4-dimethoxyphenyl)-4-oxo-thiazolidin-3-yl)methylamino]-quinazolin-4(3H)-ones. Structures of
the newly synthesized compounds were established on the basis of elemental and spectral (IR, 1H
NMR and mass) analysis.
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lsevier1. Introduction
The deﬁciency of dopamine in the basal ganglia of parkinsonian
patients has been established as a biochemical lesion in all forms
of Parkinsonism.TheLevodopa (L-DOPA), a precursor of dopa-
mine, acts on the biochemical defects of parkinsonism and is the
most effective drug available for treatment of disease. Further-
more, amantadine is another adjustment drug (dopamine facility
drug) for the treatment of Parkinsonism (Singer et al., 2006;
Luginger et al., 2000; Severy, 1977).Recently various heterocyclic
derivatives of quinazolinone have been reported to possess CNS
and antiparkinsonian activity, at substitution IInd and IIIrd posi-
tions of quinazolinones play a pivotal role inmodulating the anti-
parkinsonian properties.However, ﬁvemembered thiazolidinone
and four membered azetidinones do not appear to have been
linked with quinazolinone, so for our study has shown that the
476 S. Kumar et al.substitution of amantadinyl at IIIrd position and azetidinone and
thiozolidinone moieties at IInd position of quinazolinone yielded
better antiparkinsonian agent (Panday et al., 2005;Nathani et al.,
1989; Srivastava et al., 1987). These compounds were evaluated
for their biological activity. However, abundance of dopa decar-
boxylase inperipheral tissuehasnecessitated theuseofL-dopa for
its entry into brain to liberate dopamine by dopa decarboxylase
and therebymaintaining optimal dopamine concentration for de-
sired beneﬁcial effects. In addition, the various side effects associ-
ated with L-dopa therapy prompted the synthesis of substituted
quinazolinones containing 3,4-dimethoxydopamine moiety in
their structure in an attempt to provide preferential transport of
these compounds to brain and their possible biotransformation
to liberate dopamine and/or dopamine like substances by the ac-
tionof thedrugmetabolizing enzyme systemsand thusbeing inde-
pendent of the use of brain dopa decarboxylase. Furthermore,
thiazolidinonesandazetidinonesof variousheterocycleshavealso
been reported to possess antiparkinsonian activity (Kumar et al.,
1982; Goel et al., 2005; Srivastava et al., 1990). In the light of the
above observations we have synthesized new substituted quinaz-
olinone derivatives by incorporating azetidinones and thiazolidi-
nones moieties with the hope to get better antiparkinsonian
agents.
2. Chemistry
The synthetic route of compounds is outlined in Scheme 1.
Compounds 1a and 1b were synthesized by the reaction of
anthranilic acid and 5-bromo anthranilic acid with acidic
anhydride, respectively. Compounds 1a–1b on reaction with
amantadine yielded substituted 2-methyl benzo [1,3]oxazin-4-
ones i.e. compounds 2a–2b. Compounds 2a–2b were reacted
with bromine in glacial acetic acid to give 3-amantadinyl-2-
bromomethylsubstitutedquinazolinon-4(3H)-ones 3a–3b which
on reaction with hydrazine hydrate in methanol yielded
3-amantadinyl-2-(hydrazinylmethyl)substitutedquinazolin-4(3H)-
ones (4a–4b). Compounds 4a–4b were reacted with various
substituted aromatic aldehydes in the presence of 2% NaOH
to give 3-amantadinyl-2-[(substitutedbenzylidinehyrazinyl)
methyl]substitutedquinazolin-4(3H)-ones i.e. compounds 5a–
5l, which on reaction with thioglycolic acid in the presence
of anhydrous zinc chloride yielded 3-amantadinyl-2-[((substi-
tutedphenyl)-4-oxo-thiazolidin-3-yl)methylamino]-quinazolin-
4(3H)-ones 6a–6l. Compounds 5a–5l on further reaction with
chloroacetyl chloride in the presence of triethylamine yielded
3-amantadinyl-2-[((substitutedphenyl)-3-chloro-2-oxo-azetidin-
1-yl)methylamino]-quinazolin-4(3H)-ones (7a–7l).
3. Pharmacology
All the newly synthesized compounds were evaluated for their
antiparkinsonian activity.
The study was carried out on albino rats weighing 150–200 g
andmice 25–30 g of either sex. The animalswere fed and allowed
water ad libidum. The number of animals in each group was 5.
All the compoundswere administered in a dose of 100 mg/kg i.p.
3.1. Tremor
This activity was done by the method of Coward and Doggett
(1977). Tremors were induced by oxotremorine (OT) (0.5 mg/kg i.p) in mice 45 min after pretreatment with the test com-
pounds. After 5 min of OT injection tremors were assessed visu-
ally and scored as: 0 = no tremor; 1 = occasional tremor;
2 = intermittent tremors; 3 = continuous tremors. Each animal
of a group was scored and tremor index (mean score for each
group) was determined.
3.2. Rigidity
Reserpine (5 mg/kg i.p.) was administered in rats to produce
rigidity and after 15 min test compounds were injected. Rigidity
was measured 1 h after reserpine administration. To measure
rigidity, rats were grasped immediately below forelimbs and
slight pressure was applied upward against the hind limbs.
The degree of resistance was scored according to(Goldstein
et al., 1975): 0 = no resistance; 1 = normal resistance;
2 = complete resistance. A score of 2 was selected as criterion
for rigidity and expressed as percentage of animals showing
rigidity (score 2) in a group.
3.3. Hypokinesia
This was performed according to the method of Morpugo
(1962). It was produced by reserpine (5 mg/kg i.p.) in rats.
Locomotor activity was measured after 2 h by placing each
group of rats in a photoactometer for 15 min and total
counts were recorded. The test compounds were adminis-
tered 15 min after reserpine administration. The percent in-
crease or decrease in counts was calculated on the basis of
counts of untreated groups.
3.3.1. Catatonia
Reserpine (5 mg/kg i.p.) was administered in rats and after
15 min test compounds were administered. Catatonia was ob-
served after 4 h and was scored according to the method of
Dews (1953).
3.3.2. Acute toxicity study
The compounds which showed signiﬁcant antiparkinsonian
activity were investigated for their acute toxicity study in mice
(25–30 g) of either sex. The compounds were given orally at
graded doses to separated group of six animals. After 24 h of
administration, percent mortality in each group was observed
from the data obtained. LD50 values were calculated by the
method Smith (1960).4. Results and discussion
Compounds 5a–5l, 6a–6l and 7a–7lwere screened for their anti-
parkinsonian activity. Pharmacological data of all the synthe-
sized compounds of this series have been reported in Tables 1–3.
4.1. Antitremor activity
The 6a–6l showed better antitremor activity than L-dopa and
6g exhibited the most potent activity. Compounds 7g–7j in
general showed lesser antitremor activity than thiazolidinones.
However, these compounds exhibited almost equipotent activ-
ity as L-dopa.
Scheme 1
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Table 1 Antiparkinsonian activity of compounds 5a–5l.
Comp No. X R Oxotremorine induced
tremors in mice
(0.5 mg/kg)
Reserpine (5 mg/kg induced) LD50
mg/kg i.p.
Rigidity (%) Hypokinesia (% counts) Catatonia (mean scores)
Control 3.0 ± 0 100 14.06 3.0 ± 0
L-dopa 2.60 ± 0.24 80 30.39 2.80 ± 0.08
5a H 3,4-OCH3 2.65 ± 0.17 80 25.20 2.24 ± 0.16 >1000
5b H 2-Cl 2.67 ± 0.28 100 22.10 2.25 ± 0.18 >1000
5c H 2-Br 2.71 ± 0.13 70 21.08 2.60 ± 0.24 >1000
5d H 2-OCH3 2.73 ± 0.17 80 15.20 2.82 ± 0.22 >1000
5e H 4-OH, 3-OCH3 2.76 ± 0.21 90 14.70 2.71 ± 0.23 >1000
5f H H 2.50 ± 0.26 100 13.50 2.90 ± 0.26 >1000
5g Br 3,4-OCH3 2.55 ± 0.25 40 41.70 1.90 ± 0.19 >1000
5h Br 2-Cl 2.57 ± 0.29 50 39.40 2.43 ± 0.22 >1000
5i Br 2-Br 2.59 ± 0.25 60 36.50 2.67 ± 0.25 >1000
5j Br 2-OCH3 2.61 ± 0.32 80 34.60 2.70 ± 0.23 >1000
5k Br 4-OH, 3-OCH3 2.52 ± 0.17 70 32.10 2.90 ± 0.25 >1000
5l Br H 2.76 ± 0.30 90 30.20 2.92 ± 0.28 >1000
Table 2 Antiparkinsonian activity of compounds 6a–6l.
Comp No. X R Oxotremorine induced
tremors in mice
(0.5 mg/kg)
Reserpine (5 mg/kg induced) LD50
mg/kg i.p.
Rigidity (%) Hypokinesia (% counts) Catatonia (mean scores)
Control – – 3.0 ± 0 100 14.06 3.0 ± 0
L-dopa – – 2.6 ± 0.24 80 30.39 2.8 ± 0.08
6a H 3,4-OCH3 2.32 ± 0.19 40 57.10 1.82 ± 0.17 >1000
6b H 2-Cl 2.33 ± 0.22 30 56.40 1.86 ± 0.21 >1000
6c H 2-Br 2.37 ± 0.25 40 54.70 1.95 ± 0.24 >1000
6d H 2-OCH3 2.40 ± 0.27 30 52.90 2.10 ± 0.25 >1000
6e H 4-OH, 3-OCH3 2.42 ± 0.26 50 51.30 2.60 ± 0.23 >1000
6f H H 2.45 ± 0.29 60 49.20 2.80 ± 0.26 >1000
6g Br 3,4-OCH3 2.25 ± 0.15 10 82.70 1.30 ± 0.13 >2000
6h Br 2-Cl 2.27 ± 0.18 20 81.10 1.40 ± 0.17 >1000
6i Br 2-Br 2.28 ± 0.22 30 77.50 1.90 ± 0.19 >1000
6j Br 2-OCH3 2.27 ± 0.26 60 75.30 2.05 ± 0.23 >1000
6k Br 4-OH, 3-OCH3 2.29 ± 0.21 100 74.60 2.10 ± 0.26 >1000
6l Br H 2.30 ± 0.24 100 73.70 2.21 ± 0.29 >1000
478 S. Kumar et al.
Table 3 Antiparkinsonian activity of compounds 7a–7l.
Comp No. X R Oxotremorine induced
tremors in mice
(0.5 mg/kg)
Reserpine (5 mg/kg induced) LD50
mg/kg i.p.
Rigidity (%) Hypokinesia (% counts) Catatonia (mean scores)
Control – – 3.0 ± 0 100 14.06 3.0 ± 0
L-dopa – – 2.60 ± 0.26 80 30.39 2.80 ± 0.08
7a H 3,4-OCH3 2.52 ± 0.18 30 60.20 1.82 ± 0.23 >1000
7b H 2-Cl 2.54 ± 0.22 40 59.10 1.86 ± 0.24 >1000
7c H 2-Br 2.53 ± 0.23 50 58.30 1.95 ± 0.27 >1000
7d H 2-OCH3 2.56 ± 0.25 60 56.60 2.10 ± 0.24 >1000
7e H 4-OH, 3-OCH3 2.58 ± 0.26 40 55.40 2.60 ± 0.27 >1000
7f H H 2.59 ± 0.29 80 55.20 2.80 ± 0.29 >1000
7g Br 3,4-OCH3 2.42 ± 0.24 20 64.60 1.30 ± 0.12 >1000
7h Br 2-Cl 2.43 ± 0.26 30 63.70 1.40 ± 0.15 >1000
7i Br 2-Br 2.46 ± 0.27 40 62.40 1.90 ± 0.16 >1000
7j Br 2-OCH3 2.48 ± 0.29 40 61.30 2.05 ± 0.19 >1000
7k Br 4-OH, 3-OCH3 2.51 ± 0.31 60 63.20 2.10 ± 0.23 >1000
7l Br H 2.49 ± 0.32 60 73.70 2.21 ± 0.26 >1000
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Compounds 6g, 6h and 7g decreased rigidity by 90%, 80% and
80%, respectively, while L-dopa decreased rigidity up to only
20% at the same dose. Compounds 5a, 5d, 5j, and 7f were
equipotent to L-dopa. Compounds 5c, 5g–5i, 5k, 6a–6f, 6i–
6j, 7a–7e, 7g–7i, 7k and 7l, of this series have shown good
antirigidity activity. It can be concluded that thiazolidinone
derivatives elicited better antirigidity activity than benzylidenes
and azetidinones derivatives.
4.3. Antihypokinetic activity
Compounds 5g–5k showed almost approximately equal anti-
hypokinetic activity as L-dopa, whereas compounds 6a–6l elic-
ited better activity than standard drug. The most active
antihypokinetic compound of this series is 6g, which exhibited
82.70% antihypokinetic activity.
4.4. Anticatatonic activity
Catatonia was signiﬁcantly decreased by compounds 6g, 6h,
7g, and 7h. Compounds 5g, 6i, and 7i exhibited good anticat-
atonic activity.
4.5. Acute toxicity
The newly synthesized compounds were also tested for approx-
imate lethal dose LD50 and were found to exhibit a higher value
of LD50 i.e. more than 1000 mg/kg i.p. except compound 6g,which exhibited LD50 of more than 2000 mg/kg i.p. (maximum
dose tested), thus indicating the safer nature of the compounds.
5. Conclusion
Thiazolidinone derivatives showed more potent antiparkinso-
nian activity than azetidinone derivatives. Moreover, the sub-
stitution with 3,4-dimethoxyphenyl group was found to
beneﬁcial for antiparkinsonian activity.
6. Experimental protocols
6.1. Chemistry
All reagents and solvents were generally used as received
from the commercial supplier. Reactions were routinely per-
formed in an oven-dried glassware. The melting points of
compounds were determined in open capillaries with the help
of thermonic melting point apparatus and were uncorrected.
The purity of the compounds was checked by thin layer
chromatography (TLC) performed on silica gel G coated
plate of 0.5 mm thickness. The eluent was a mixture of dif-
ferent polar and nonpolar solvents in different proportions
and spots were visualized under iodine chamber. Elemental
analysis (C, H, N) of all the compounds was determined
through the Perkin–Elmer 2400 elemental analyzer and re-
sults were found within ±0.4% of theoretical values. Infra
red (IR) spectra were recorded in KBr on the Perkin–El-
mer-spectrum RX-I instrument and tmax was recorded in
cm1. 1H NMR spectra were recorded by the Bruker DR-
X-400 FT-NMR instrument using CDCl3 and DMSO-d6 as
480 S. Kumar et al.solvents and tetramethysilane (TMS) as an internal reference
as d (ppm).6.1.1. General procedure for synthesis of 2-methyl-6-
substitutedbenzo(1,3)oxazin-4-ones (1a–1b)
These compounds were prepared according to the method of
Bogert and Soil (1907). A mixture of unsubstituted/6-bromo-
anthranilic acid (1.0 mol) and acetic anhydride (0.02 mol)
was reﬂuxed for 2–3 h with occasional stirring. The excess of
acetic anhydride was distilled off. On cooling, a solid was
separated out which was ﬁltered and washed with appropriate
solvent and dried 1a–1b.
6.1.1.1. 2-Methyl-4H-benzo(1,3)oxazin-4-one (1a). Yield 86%
(Methanol): m.p. 79–81 C; IR (KBr) tmax in cm1 1701
(C‚O), 1610 (C. . .•C of aromatic ring), 1570 (C‚N), 1302
(C–N); 1H NMR (CDCl3) d in ppm: 6.65–7.73 (m, 4H, Ar-
H), 1.31 (s, 3H, CH3). MS: [M]
+ at m/z 161.16. Anal. Calc.
for C9H7NO2: C, 67.07; H, 4.38; N, 8.69. Found: C, 67.15;
H, 4.35; N, 8.65%.
6.1.1.2. 6-Bromo-2-methyl-4H-benzo(1,3)oxazin-4-one (1b).
Yield 83% (Petroleum ether): m.p. 80 C; IR (KBr) tmax in
cm1 1704 (C‚O), 1612 (C. . .•C of aromatic ring), 1575
(C‚N), 1304 (C–N), 610 (C–Br); 1H NMR (CDCl3) d in
ppm: 6.71–7.65 (m, 3H, Ar-H), 1.30 (s, 3H, CH3). MS: [M]
+
at m/z 240.5. Anal. Calc. for C9H6BrNO2: C, 45.03; H, 2.52;
N, 5.83. Found: C, 45.15; H, 2.55; N, 5.83%.
6.1.2. General procedure for the synthesis of 3-amantadinyl-2-
methyl-6-monosubstitutedquinazolin-4(3H)-ones 2a–2b
To a solution of compound 1a–1b amantadine (0.02 mol) was
added, the mixture was heated on a free ﬂame for 10–20 min in
a conical ﬂask. After the disappearance of water droplets in a
conical ﬂask it was kept at room temperature. On cooling a jel-
ly like mass was obtained which was dissolved in ethanol, was
reﬂuxed and poured into water. The solid thus obtained was
ﬁltered, dried and ﬁnally recrystallized from the appropriate
solvent to obtain compounds 2a–2b.
6.1.2.1. 3-Amantadinyl-2-methylquinazolin-4(3H)–one (2a).
Yield 82% (Methanol): m.p. 205 C; IR (KBr) tmax in cm1:
1706 (C‚O), 1615 (C. . .•C of aromatic ring), 1571 (C‚N),
1300 (C–N); 1H NMR (DMSO-d6) d in ppm: 6.73–7.70 (m,
4H, Ar-H), 1.27 (s, 3H, CH3), 1.30 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 294.39. Anal. Calc. for C19H22N2O:
C, 77.52; H, 7.53; N, 9.52. Found: C, 77.63; H, 7.67; N, 9.44%.
6.1.2.2. 3-Amantadinyl-6-bromo-2-methylquinazolin-4(3H)-one
(2b). Yield 78% (Ethanol): m.p. 201 C; IR (KBr) tmax in cm
1: 1708 (C‚O), 1616 (C. . .•C of aromatic ring), 1571 (C‚N),
1302 (C–N), 613 (C–Br); 1H NMR (CDCl3) d in ppm: 1.29 (m,
15H, amantadinyl ring), 6.78–7.37 (m, 3H, Ar-H), 1.32 (s, 3H,
CH3). MS: [M]
+ at m/z 373.29. Anal. Calc. for C19H21BrN2O:
C, 61.13; H, 5.67; N, 7.50. Found: C, 61.22; H, 5.65; N, 7.53%.
6.1.3. General procedure for synthesis of 3-amantadinyl-2-
bromomethylsubstitutedquinazolin-4-(3H) ones 3a–3b
Bromine (0.4 mol) in acetic acid was added dropwise to the solu-
tion of compound 2a–ab in acetic acid (50 mL). The reactionmixture was poured onto crushed ice, then left overnight at
room temperature. The precipitate thus obtained was recrystal-
lized with suitable solvents to furnish compounds 3a–3b.
6.1.3.1. 3-Amantadinyl-2-bromomethylquinazolin-4(3H)-one
(3a). Yield 76% (Methanol): m.p. 198 C; IR (KBr) tmax
in cm1: 1710 (C‚O), 1619 (C. . .•C of aromatic ring),
1579 (C‚N), 1305 (C–N); 1H NMR (CDCl3) d in ppm:
6.67–7.72 (m, 4H, Ar-H), 1.32 (m, 15H, amantadinyl ring),
1.25 (s, 2H, CH2). MS: [M]
+ at m/z 373.29. Anal. Calc.
for C19H21BrN2O: C, 61.13; H, 5.67; N, 7.50. Found: C,
61.24; H, 5.58; N, 7.43%.
6.1.3.2. 3-Amantadinyl-6-bromo-2-(bromomethyl)quinazolin-
4(3H)-one (3b). Yield 75% (Methanol): m.p. 201 C; IR
(KBr) tmax in cm
1: 1712 (C‚O), 1621 (C. . .•C of aromatic
ring), 1574 (C‚N), 1303 (C–N), 615 (C–Br); 1H NMR
(DMSO-d6) d in ppm: 6.79–7.92 (m, 3H, Ar-H), 1.31 (s, 2H,
CH2), 1.25 (m, 15H, amantadinyl ring). MS: [M]
+ at m/z
452.18. Anal. Calc. for C19H20Br2N2O: C, 50.47; H, 4.46; N,
6.20. Found: C, 50.43; H, 4.45; N, 6.25%.
6.1.4. General procedure for synthesis of 3-amantadinyl-2-
(hydrazinylmethyl)substitutedquinazolin-4(3H)-one 4a–4b
A compound 3a–3b (0.01 mol) and hydrazine hydrate
(0.02 mol) in methanol were reﬂuxed for 10 h. The excess of
solvent was distilled off and the reaction mixture was poured
onto ice. The solid thus obtained was ﬁltered washed with
water dried and recrystallized from appropriate solvents to
yield compounds 4a–4b.
6.1.4.1. 3-Amantadinyl-2-hydrazinylmethylquinazolin-4(3H)-
one (4a). Yield 73% (Ethanol): m.p. 195 C; IR (KBr) tmax
in cm1: 3341 (N–H), 1713 (C‚O), 1625 (C. . .•C of aromatic
ring), 1579 (C‚N), 1306 (C–N), 1260 (N–N), 624 (C–Br); 1H
NMR (CDCl3) d in ppm: 8.34 (s, 1H, NH exchangeable with
D2O), 8.15 (s, 2H, NH2), 6.68–7.67 (m, 4H, Ar-H), 3.28 (d,
2H, J= 9.1 Hz, CH2NH), 1.34 (m, 15H, amantadinyl ring).
MS: [M]+ at m/z 324.42. Anal. Calc. for C19H24N4O: C,
70.23; H, 7.46; N, 17.27. Found: C, 70.22; H, 7.45; N, 17.23%.
6.1.4.2. 3-Amantadinyl-6-bromo-2-hydrazinylmethyl)quinazo-
lin-4(3H)-one (4b). Yield 70% (Ethanol): m.p. 193 C; IR
(KBr) tmax in cm
1: 3345 (N–H), 1710 (C‚O), 1617
(C. . .•C of aromatic ring), 1581 (C‚N), 1304 (C–N), 614
(C–Br); 1H NMR (CDCl3) d in ppm: 8.12 (s, 1H, NH
exchangeable with D2O), 8.10 (s, 2H, NH2), 6.62–7.58 (m,
3H, Ar-H), 3.28 (d, 2H, J= 9.1 Hz, CH2NH), 1.33 (m,
15H, amantadinyl ring), MS: [M]+ at m/z 403.32. Anal.
Calc. for C19H23BrN4O: C, 56.58; H, 5.75; N, 13.89. Found:
C, 56.55; H, 5.78; N, 13.85%.
6.1.5. General procedure for synthesis of 3-amantadinyl-2-[2-
(substitutedbenzylidine)hydrazinyl]methylquinazolin-4(3H)-
ones 5a–5l
A mixture of compound 4a–4b (0.02 mol) and substituted
benzaldehydes (0.01 mol) was dissolved in absolute ethanol
and (60 mL) in the presence of few drops of glacial acid. The
reaction mixture was reﬂuxed for 12 h and poured onto
crushed ice and the resultant solid was recrystallized from suit-
able solvents to yield compounds 5a–5l.
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zinyl)methyl]quinazolin-4(3H)-one (5a). Yield 75% (Metha-
nol): m.p. 182 C; IR (KBr) tmax in cm1: 3340 (N–H), 1725
(C‚O), 1620 (C. . .•C of aromatic ring), 1580 (C‚N), 1570
(N‚CH), 1309 (C–N), 1290 (N–N), 1224 (OCH3);
1H NMR
(DMSO-d6) d in ppm: 8.29 (s, 1H, CH-Ar), 8.13 (s, 1H, NH
exchangeable with D2O), 6.69–7.72 (m, 7H, Ar-H), 3.35 (d,
2H, J= 9.1 Hz, CH2NH), 3.29 (s, 6H, 2 · OCH3), 1.31 (m,
15H, amantadinyl ring). MS: [M]+ at m/z 472.58. Anal. Calc.
for C28H32N4O3: C, 71.16; H, 6.83; N, 11.86. Found: C, 71.15;
H, 6.85; N, 11.84%.
6.1.5.2. 3-Amantadinyl-2-[(2-(2-chlorobenzylidine)hydrazi-
nyl)methyl]quinazolin-4(3H)-one (5b). Yield 74% (DMF):
m.p. 175 C; IR (KBr) tmax in cm1: 3343 (N–H), 1719
(C‚O), 1625 (C. . .•C of aromatic ring), 1583 (C‚N), 1570
(N‚CH), 1310 (C–N), 1293 (N–N), 726 (C–Cl); 1H NMR
(CDCl3) d in ppm: 8.40 (s, 1H, NH exchangeable with D2O),
8.30 (s, 1H, CH-Ar), 6.59–7.62 (m, 8H, Ar-H), 3.45 (d, 2H,
J= 9.1 Hz, CH2NH), 1.35 (m, 15H, amantadinyl ring). MS:
[M]+ at m/z 446.97. Anal. Calc. for C26H27ClN4O: C, 69.87;
H, 6.09; N, 12.53. Found: C, 69.85; H, 6.13; N, 12.54%.
6.1.5.3. 3-Amantadinyl-2-[(2-(2-bromobenzylidine)hydrazi-
nyl)methyl]quinazolin-4(3H)-one (5c). Yield 71% (Ethanol):
m.p. 173 C; IR (KBr) tmax in cm1: 3346 (N–H), 1716
(C‚O), 1624 (C. . .•C of aromatic ring), 1585 (C‚N), 1574
(N‚CH), 1311 (C–N), 1295 (N–N), 612 (C–Br); 1H NMR
(DMSO-d6) d in ppm: 8.32 (s, 1H, CH-Ar), 8.20 (s, 1H, NH
exchangeable with D2O), 6.62–7.63 (m, 8H, Ar-H), 3.43 (d,
2H, J= 9.1 Hz, CH2NH), 1.38 (m, 15H, amantadinyl ring).
MS: [M]+ at m/z 491.42. Anal. Calc. for C26H27BrN4O: C,
63.55; H, 5.54; N, 11.40. Found: C, 63.52; H, 5.52; N, 11.43%.
6.1.5.4. 3-Amantadinyl-3-[(2-(2-methoxybenzylidine)hydrazi-
nyl)methyl]quinazolin-4(3H)-one (5d). Yield 68% (DMF):
m.p. 167 C; IR (KBr) tmax in cm1: 3343 (N–H), 1718
(C‚O), 1626 (C. . .•C of aromatic ring), 1589 (C‚N), 1575
(N‚CH), 1311 (C–N), 1293 (N–N), 1226 (OCH3);
1H NMR
(CDCl3) d in ppm: 8.45 (s, 1H, NH exchangeable with D2O),
8.29 (s, 1H, CH-Ar), 6.66–7.72 (m, 8H, Ar-H), 3.46 (s, 3H,
OCH3), 3.43 (d, 2H, J= 9.1 Hz, CH2NH), 1.30 (m, 15H,
amantadinyl ring). MS: [M]+ at m/z 442.24. Anal. Calc. for
C27H30N4O2: C, 73.28; H, 6.83; N, 12.66. Found: C, 73.25;
H, 6.86; N, 12.63%.
6.1.5.5. 3-Amantadinyl-2-[(2-(4-hydroxy-3-methoxybenzyli-
dine)hydrazinyl)methyl] quinazolin-4(3H)-one (5e). Yield
64% (Methanol), m.p. 176 C; IR (KBr) tmax in cm1: 3430
(OH), 3345 (N–H), 1718 (C‚O), 1622 (C. . .•C of aromatic
ring), 1588 (C‚N), 1579 (N‚CH), 1308 (C–N), 1294 (N–
N), 1223 (OCH3);
1H NMR (CDCl3) d in ppm: 8.33 (s, 1H,
CH-Ar), 8.32 (s, 1H, NH exchangeable with D2O), 11.15 (s,
1H, OH exchangeable with D2O), 6.69–7.75 (m, 7H, Ar-H),
3.42 (s, 3H, OCH3), 3.37 (d, 2H, J= 9.1 Hz, CH2NH), 1.34
(m, 15H, amantadinyl ring). MS: [M]+ at m/z 458.55. Anal.
Calc. for C27H30N4O3: C, 70.72; H, 6.59; N, 12.22. Found:
C, 70.76; H, 6.54; N, 12.24%.
6.1.5.6. 3-Amantadinyl-2-(2-benzylidine)hydrazinyl)methyl]
quinazolin-4(3H)-one (5f). Yield 62% (Acetone): m.p.
171 C; IR (KBr) tmax in cm1: 3348 (N–H), 1737 (C‚O),1623 (C. . .•C of aromatic ring), 1586 (N‚CH), 1582 (C‚N),
1307 (C–N), 1291 (N–N); 1H NMR (CDCl3) d in ppm: 8.35
(s, 1H, CH-Ar), 8.25 (s, 1H, NH exchangeable with D2O),
6.65–7.63 (m, 9H, Ar-H), 1.31 (d, 2H, J= 9.2 Hz, CH2NH),
1.23 (m,15H, amantadinyl ring). MS: [M]+ at m/z 412.53.
Anal. Calc. for C26H28N4O: C, 75.10; H, 6.84; N, 13.58.
Found: C, 75.15; H, 6.91; N, 13.46%.
6.1.5.7. 3-Amantadinyl-6-bromo-2-[(2-(3,4-dimethoxybenzyli-
dine)hydrazinyl)methyl] quinazolin-4(3H)-one (5g). Yield
59% (Ethanol): m.p. 169 C; IR (KBr) tmax in cm1: 3349
(N–H), 1726 (C‚O), 1626 (C. . .•C of aromatic ring), 1588
(C‚N), 1570 (N‚CH), 1312 (C–N), 1291 (N–N), 1224
(OCH3), 614 (C–Br);
1H NMR (DMSO-d6) d in ppm: 8.34
(s, 1H, CH-Ar), 8.46 (s, 1H, NH exchangeable with D2O),
6.69–7.72 (m, 6H, Ar-H), 3.47 (d, 2H, J= 9.1 Hz, CH2NH),
2.29 (s, 6H, 2 · OCH3), 1.31 (m, 15H, amantadinyl ring).
MS: [M]+ at m/z 551.47. Anal. Calc. for C28H31BrN4O3: C,
60.98; H, 5.67; N, 10.16. Found: C, 60.95; H, 5.65; N, 10.19%.
6.1.5.8. 3-Amantadinyl-6-bromo-2-[(2-(2-chlorobenzyli-
dine)hydrazinyl)methyl]quinazolin-4(3H)-one (5h). Yield
56% (DMF): m.p. 168 C; IR (KBr) tmax in cm1: 3345 (N–
H), 1720 (C‚O), 1624 (C. . .•C of aromatic ring), 1585
(C‚N), 1574 (N‚CH), 1313 (C–N), 1291 (N–N), 623 (C–
Cl), 615 (C–Br); 1H NMR (CDCl3) d in ppm: 8.46 (s, 1H,
NH exchangeable with D2O), 8.30 (s, 1H, CH-Ar), 6.59–7.62
(m, 7H, Ar-H), 3.44 (d, 2H, J= 9.1 Hz, CH2NH), 1.35 (m,
15H, amantadinyl ring), MS: [M]+ at m/z 525.87. Anal. Calc.
for C26H26BrClN4O: C, 59.38; H, 4.98; N, 10.65. Found: C,
59.35; H, 4.95; N, 10.63%.
6.1.5.9. 3-Amantadinyl-6-bromo-2-[(2-(2-bromobenzyli-
dine)hydrazinyl)methyl] quinazolin-4(3H)-one (5i). Yield
52% (Acetone): m.p. 165 C; IR (KBr) tmax in cm1: 3341
(N–H), 1715 (C‚O), 1627(C. . .•C of aromatic ring), 1589
(C‚N), 1576 (N‚CH), 1313 (C–N), 612 (C–Br); 1H NMR
(DMSO-d6) d in ppm: 8.32 (s, 1H, CH-Ar), 8.30 (s, 1H, NH
exchangeable with D2O), 6.62–7.63 (m, 7H, Ar-H), 3.45 (d,
2H, J= 9.1 Hz, CH2NH), 1.38 (m, 15H, amantadinyl ring),
MS: [M]+ at m/z 570.32. Anal. Calc. for C26H26Br2N4O: C,
54.76; H, 4.60; N, 9.82. Found: C, 54.78; H, 4.65; N, 9.66%.
6.1.5.10. 3-Amantadinyl-6-bromo-2-[(2-(2-methoxybenzyli-
dine)hydrazinyl)methyl]quinazolin-4(3H)-one (5j). Yield
56% (Methanol): m.p. 163 C; IR (KBr) tmax in cm1: 3342
(N–H), 1629 (C. . .•C of aromatic ring), 1720 (C‚O), 1590
(C‚N), 1578 (N‚CH), 1313 (C–N), 1294 (N–N), 1225
(OCH3), 618 (C–Br);
1H NMR (CDCl3) d in ppm: 8.45 (s,
1H, NH exchangeable with D2O), 8.34 (s, 1H, CH-Ar), 6.66–
7.72 (m, 7H, Ar-H), 3.50 (d, 2H, J= 9.1 Hz, CH2NH), 3.30
(s, 3H, OCH3), 1.30 (m, 15H, amantadinyl ring). MS: [M]
+
at m/z 521.45. Anal. Calc. for C27H29BrN4O2: C, 62.19; H,
5.61; N, 10.74. Found: C, 62.15; H, 5.65; N, 10.76%.
6.1.5.11. 3-Amantadinyl-6-bromo-2-[(2-(4-hydroxy-3-meth-
oxybenzylidine)hydrazinyl)methyl]quinazolin-4(3H)-one (5k).
Yield 53% (Ethanol): m.p. 160 C; IR (KBr) tmax in cm1:
3433 (OH), 3342 (N–H), 1721 (C‚O), 1624 (C. . .•C of aro-
matic ring), 1589 (C‚N), 1580 (N‚CH), 1313 (C–N), 1294
(N–N), 1227 (OCH3), 618 (C–Br);
1H NMR (CDCl3) d in
ppm: 8.48 (s, 1H, NH exchangeable with D2O), 8.35 (s, 1H,
482 S. Kumar et al.CH-Ar), 10.95 (s, 1H, OH exchangeable with D2O), 6.69–7.75
(m, 6H, Ar-H), 3.48 (d, 2H, J= 9.0 Hz, CH2NH), 3.46 (s, 3H,
OCH3), 1.34 (m, 15H, amantadinyl ring). MS: [M]
+ at m/z
537.45. Anal. Calc. for C27H29BrN4O3: C, 60.34; H, 5.44; N,
10.42. Found: C, 60.36; H, 5.46; N, 10.40%.
6.1.5.12. 3-Amantadinyl-6-bromo-2-[(2-benzylidine)hydrazi-
nyl)methyl]quinazolin-4(3H)-one (5l). Yield 52% (Ethanol):
m.p. 162 C; IR (KBr) tmax in cm1: 3350 (N–H), 1722
(C‚O), 1627 (C. . .•C of aromatic ring), 1591 (C‚N), 1583
(N‚CH), 1312 (C–N), 1290 (N–N); 1H NMR (DMSO-d6) d
in ppm: 8.47 (s, 1H, NH exchangeable with D2O), 6.65–7.63
(m, 8H, Ar-H), 3.51 (d, 2H, J= 9.1 Hz, CH2NH), 3.36 (s,
1H, CH-Ar), 1.23 (m, 15H, amantadinyl ring). MS: [M]+ at
m/z 491.42. Anal. Calc. for C26H27BrN4O: C, 63.55; H, 5.54;
N, 11.40. Found: C, 63.54; H, 5.59; N, 11.43%.
6.1.6. General procedure for synthesis of 3-amantadinyl-2-
[((substitutedphenyl)-4-oxo-thiazolidin-1-yl)
methylamino]quinazolin-4(3H)-ones 6a–6l
To a solution of compound 5a–5l (0.01 mol) and anhydrous
ZnCl2 in dry benzene (50 mL), thioglycolic acid (0.02 mol)
was added dropwise with stirring at ambient temperature
and the reaction mixture was kept for 3 days at room temper-
ature and then reﬂuxed for 14 h. The reaction mixture was ﬁl-
tered. The ﬁltrate was concentrated and poured on crushed ice.
The resultant solid was recrystallized from appropriate solvent
to yield the desired compounds 6a–6l.
6.1.6.1. 3-Amantadinyl-2-[((3,4-dimethoxyphenyl)-4-oxo-thiazoli-
din-3-yl)methylamino]-quinazolin-4(3H)-one (6a). Yield 55%
(DMF): m.p. 175 C; IR(KBr) tmax in cm1: 1768 (C‚O),
1626 (C. . .•C of aromatic ring), 1591 (C‚N), 1312 (C–N),
1224 (OCH3), 674 (C–S–C);
1H NMR (DMSO-d6) d in ppm:
8.48 (s, 1H, NH exchangeable with D2O), 6.69–7.72 (m, 7H,
Ar-H), 5.93 (s, 1H, CH-Ar), 3.53 (s, 2H, CH2-S), 2.85 (s,
6H, 2 · OCH3), 2.52 (d, 2H, J= 9.1 Hz, CH2NH), 1.17 (m,
15H, amantadinyl ring). MS: [M]+ at m/z 546.68. Anal. Calc.
for C30H34N4O4S: C, 65.91; H, 6.27; N, 10.25. Found: C,
65.92; H, 6.25; N, 10.23%.
6.1.6.2. 3-Amantadinyl-2-[((2-chlorophenyl)-4-oxo-thiazolidin-
3-yl)methylamino]-quinazolin-4(3H)-one (6b). Yield 60%
(Ethanol): m.p. 173 C; IR (KBr) tmax in cm1: 1772
(C‚O), 1625 (C. . .•C of aromatic ring), 1532 (C‚N), 1257
(C–N), 728 (C–Cl), 678 (C–S–C); 1H NMR (CDCl3) d in
ppm: 8.34 (s, 1H, NH exchangeable with D2O), 6.65–7.69
(m, 8H, Ar-H), 5.83 (s, 1H, CH-Ar), 3.93 (s, 2H, CH2-S),
2.87 (d, 2H, J= 9.1 Hz, CH2NH), 1.17 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 521.07. Anal. Calc. for
C28H29ClN4O2S: C, 64.54; H, 5.61; N, 10.75. Found: C,
64.42; H, 5.32; N, 10.43%.
6.1.6.3. 3-Amantadinyl-2-[((2-bromophenyl)-4-oxo-thiazolidin-
3-yl)methylamino]-quinazolin-4(3H)-one (6c). Yield 64%
(Methanol): m.p. 167 C; IR (KBr) tmax in cm1: 1772
(C‚O), 1627 (C. . .•C of aromatic ring), 1531 (C‚N), 1306
(C–N), 677 (C–S–C), 612 (C–Br); 1H NMR (CDCl3) d in
ppm: 8.23 (s, 1H, NH exchangeable with D2O), 6.69–7.75
(m, 8H, Ar-H), 5.86 (s, 1H, CH-Ar), 3.60 (s, 2H, CH2-S),
2.54 (d, 2H, J= 9.1 Hz, CH2NH), 1.25 (m, 15H amantadinyl
ring). MS: [M]+ at m/z 565.52. Anal. Calc. forC28H29BrN4O2S: C, 59.47; H, 5.17; N, 9.91; Found: C,
59.49; H, 5.14; N, 9.93%.
6.1.6.4. 3-Amantadinyl-2-[((2-methoxyphenyl)-4-oxothiazoli-
din-3-yl)methylamino]-quinazolin-4(3H)-one (6d). Yield 58%
(Methanol): m.p. 163 C; IR (KBr) tmax in cm1: 1773
(C‚O), 1626 (C. . .•C of aromatic ring), 1529 (C‚N), 1308
(C–N), 1220 (OCH3), 676 (C–S–C);
1H NMR (DMSO-d6) d
in ppm: 8.35 (s, 1H, NH exchangeable with D2O), 6.68–7.78
(m, 8H, Ar-H), 5.89 (s, 1H, CH-Ar), 3.65 (s, 2H, CH2-S),
2.85 (s, 3H, OCH3), 2.69 (d, 2H, J= 9.2 Hz, CH2NH), 1.18
(m, 15H, amantadinyl ring). MS: [M]+ at m/z 516.65. Anal.
Calc. for C29H32N4O3S: C, 67.42; H, 6.24; N, 10.84. Found:
C, 67.42; H, 6.22; N, 10.83%.
6.1.6.5. 3-Amantadinyl-2-[((4-hydroxy-3-methoxyphenyl)-4-
oxo-thiazolidin-3-yl)methyl amino]-quinazolin-4(3H)-one
(6e). Yield 53% (DMF): m.p. 160 C; IR (KBr) tmax in cm
1: 3434 (OH), 1776 (C‚O), 1619 (C. . .•C of aromatic ring),
1532 (C‚N), 1313 (C–N), 1228 (OCH3), 673 (C–S–C);
1H
NMR (CDCl3) d in ppm: 8.38 (s, 1H, NH exchangeable with
D2O), 11.12 (s, 1H, OH exchangeable with D2O), 6.75–7.70
(m, 7H, Ar-H), 5.65 (s, 1H, CH-Ar), 3.69 (s, 2H, CH2-S),
2.83 (s, 3H, OCH3), 2.68 (d, 2H, J= 9.1 Hz, CH2NH), 1.18
(m, 15H, amantadinyl ring). MS: [M]+ at m/z 532.65. Anal.
Calc. for C29H32N4O4S: C, 65.39; H, 6.06; N, 10.52. Found:
C, 65.35; H, 6.08; N, 10.56%.
6.1.6.6. 3-Amantadinyl-2-[((phenyl)-4-oxo-thiazolidin-3-
yl)methylamino]-quinazolin-4(3H)-one (6f). Yield 51%
(Methanol): m.p. 158 C; IR (KBr) tmax in cm1: 1777
(C‚O), 1622 (C. . .•C of aromatic ring), 1587 (C‚N), 1315
(C–N), 679 (C–S–C); 1H NMR (CDCl3) d in ppm: 8.36 (s,
1H, NH exchangeable with D2O), 6.74–7.72 (m, 9H, Ar-H),
5.62 (s, 1H, CH-Ar), 3.72 (s, 2H, CH2-S), 2.85 (d, 2H,
J= 9.1 Hz, CH2NH), 1.24 (m, 15H, amantadinyl ring). MS:
[M]+ at m/z 486.63. Anal. Calc. for C28H30N4O2S: C, 69.11;
H, 6.21; N, 11.51. Found: C, 69.15; H, 6.26; N, 11.54%.
6.1.6.7. 3-Amantadinyl-6-bromo-2-[((3,4-dimethoxyphenyl)-4-
oxo-thiazolidin-3-yl)methyl amino]-quinazolin-4(3H)-one
(6g). Yield 55% (Ethanol): m.p. 155 C; IR (KBr) tmax in
cm1: 1780 (C‚O), 1621 (C. . .•C of aromatic ring), 1584
(C‚N), 1310 (C–N), 1228 (OCH3), 679 (C–S–C), 617
(C–Br); 1HNMR (CDCl3). d in ppm: 8.32 (s, 1H, NH exchange-
able with D2O), 6.65–7.62 (m, 6H, Ar-H), 5.68 (s, 1H, CH-Ar),
3.66 (s, 2H, CH2-S), 3.40 (s, 6H, 2 · OCH3), 2.84 (d, 2H,
J= 9.1 Hz, CH2NH), 1.28 (m, 15H, amantadinyl ring). MS:
[M]+ at m/z 625.58. Anal. Calc. for C30H33BrN4O4S: C, 57.60;
H, 5.32; N, 8.96. Found: C, 57.62; H, 5.35; N, 8.98%.
6.1.6.8. 3-Amantadinyl-6-bromo-2-[(2-chlorophenyl)-4-oxo-
thiazolidin-3-yl)methylamino]-quinazolin-4(3H)-one (6h).
Yield 58% (Acetone): m.p. 150 C; IR (KBr) tmax in cm1:
1771 (C‚O), 1621 (C. . .•C of aromatic ring), 1582 (C‚N),
1306 (C–N), 729 (C–Cl), 682 (C–S–C); 1H NMR (DMSO-d6)
d in ppm: 8.35 (s, 1H, NH exchangeable with D2O), 6.67–
7.76 (m, 7H, Ar-H), 5.65 (s, 1H, CH-Ar), 3.68 (s, 2H, CH2-
S), 2.87 (d, 2H, J= 9.2 Hz, CH2NH), 1.32 (m, 15H, amantadi-
nyl ring). MS: [M]+ at m/z 599.97. Anal. Calc. for
C28H28BrClN4O2S: C, 56.05; H, 4.70; N, 9.34. Found: C,
55.02; H, 4.73; N, 9.35%.
Synthesis of new azetidinonyl/thiazolidinonyl quinazolinone derivatives as antiparkinsonian agents 4836.1.6.9. 3-Amantadinyl-6-bromo-2-[((2-bromophenyl)-4-oxo-
thiazolidin-3-yl)methylamino]-quinazolin-4(3H)-one (6i).
Yield 64% (Methanol): m.p. 148 C; IR (KBr) tmax in cm1:
1776 (C‚O), 1623 (C. . .•C of aromatic ring), 1591 (C‚N),
1309 (C–N), 678 (C–S–C), 618 (C–Br); 1H NMR (CDCl3) d
in ppm: 8.39 (s, 1H, NH exchangeable with D2O), 6.63–7.75
(m, 7H, Ar-H), 5.66 (s, 1H, CH-Ar), 3.65 (s, 2H, CH2-S),
2.84 (d, 2H, J= 9.1 Hz, CH2NH), 1.36 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 644.42. Anal. Calc. for
C28H28Br2N4O2S: C, 52.19; H, 4.38; N, 8.69. Found: C,
52.16; H, 4.37; N, 8.65%.
6.1.6.10. 3-Amantadinyl-6-bromo-2-[((2-methoxyphenyl)-4-
oxo-thiazolidin-3-yl)methyl amino]-quinazolin-4(3H)-one
(6j). Yield 67% (Ethanol): m.p. 145 C; IR (KBr) tmax in
cm1: 1777 (C‚O), 1629 (C. . .•C of aromatic ring), 1579
(C‚N), 1305 (C–N), 1226 (OCH3), 675 (C–S–C), 622 (C–
Br); 1H NMR (DMSO-d6) d in ppm: 8.40 (s, 1H, NH
exchangeable with D2O), 6.67–7.74 (m, 7H, Ar-H), 5.68 (s,
1H, CH-Ar), 3.68 (s, 2H, CH2-S), 3.55 (s, 3H, OCH3), 2.88
(d, 2H, J= 9.1 Hz, CH2NH), 1.38 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 595.55. Anal. Calc. for
C29H31BrN4O3S: C, 58.49; H, 5.25; N, 9.41. Found: C,
58.45; H, 5.17; N, 9.43%.
6.1.6.11. 3-Amantadinyl-6-bromo-2-[((4-hydroxy-3-methoxy-
phenyl)-4-oxo-thiazolidin-3-yl)methylamino]-quinazolin-4(3H)-
one (6k). Yield 53% (Ethanol): m.p. 141 C; IR (KBr) tmax in
cm1: 3440 (OH), 1773 (C‚O), 1625 (C. . .•C of aromatic ring),
1592 (C‚N), 1312 (C–N), 1228 (OCH3), 680 (C–S–C), 624
(C–Br); 1H NMR (DMSO-d6) d in ppm: 11.16 (s, 1H, OH
exchangeable with D2O), 8.44 (s, 1H, NH exchangeable with
D2O), 6.80–7.79 (m, 6H, Ar-H), 5.68 (s, 1H, CH-Ar), 3.72 (s,
2H, CH2-S), 3.62 (s, 3H, OCH3), 2.92 (d, 2H, J= 9.1 Hz,
CH2NH), 1.35 (m, 15H, amantadinyl ring). MS: [M]
+ at m/z
611.55. Anal. Calc. for C29H31BrN4O4S: C, 56.96; H, 5.11;
N, 9.16. Found: C, 56.94; H, 4.16; N, 9.12%.
6.1.6.12. 3-Amantadinyl-6-bromo-2-[((phenyl)-4-oxo-thiazoli-
din-3-ylmethylamino]-quinazolin-4(3H)-one (6l). Yield 61%
(Methanol): m.p. 145 C; IR (KBr) tmax in cm1: 1772
(C‚O), 1628 (C. . .•C of aromatic ring), 1587 (C‚N), 1305
(C–N), 681 (C–S–C), 615 (C–Br); 1H NMR (CDCl3) d in
ppm: 8.47 (s, 1H, NH exchangeable with D2O), 6.75–7.81
(m, 8H, Ar-H), 5.66 (s, 1H, CH-Ar), 3.70 (s, 2H, CH2-S),
2.90 (d, 2H, J= 9.1 Hz, CH2NH), 1.45 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 565.52. Anal. Calc. for
C28H29BrN4O2S: C, 59.47; H, 5.17; N, 9.91. Found: C,
59.46; H, 5.15; N, 9.93%.
6.1.7. General procedure for synthesis of 3-amantadinyl-2-
[(substitutedphenyl)-3-chloro-2-oxo-azetidin-1-yl)
methylamino]-quinazolin-4(3H)-ones 7a–7l
To a solution of compounds 6a–6l (0.01 mol) and triethylamine
(5–6 drops) in dry benzene, mono chloro acetyl chloride
(0.15 mol) was added dropwise at 50 C. The reaction mixture
was stirred for 40 min at room temperature and reﬂuxed for 7 h.
The reaction mixture was ﬁltered to remove triethylamine hydro-
gen chloride and the resultant solution was poured onto crushed
ice with constant stirring. The solid thus obtained was recrystal-
lized from suitable solvents to yield the desired compounds 7a–7l.6.1.7.1. 3-Amantadinyl-2-[((3,4-dimethoxyphenyl)-3-chloro-2-
oxo-azetidin-3-yl)methyl amino]-quinazolin-4(3H)-one (7a).
Yield 52% (Methanol): m.p. 175 C; IR (KBr) tmax in cm1:
1755 (C‚O) 1625 (C. . .•C of aromatic ring), 1575 (C‚N),
1322 (C–N), 727 (C–Cl); 1H NMR (CDCl3) d in ppm: 8.35
(s, 1H, NH exchangeable with D2O), 6.64–7.75 (m, 7H, Ar-
H), 5.80 (s, 1H, CH-Ar), 6.42 (d, 1H, J= 6.5 Hz, CHCl),
3.70 (d, 2H, J= 9.1 Hz, CH2NH), 3.45 (s, 6H, 2 · OCH3),
1.13 (m, 15H, amantadinyl ring). MS: [M]+ at m/z 549.06.
Anal. Calc. for C30H33ClN4O4: C, 65.63; H, 6.06; N, 10.20.
Found: C, 65.59; H, 6.12; N, 10.27%.
6.1.7.2. 3-Amantadinyl-2-[(2-chlorophenyl)-3-chloro-2-oxo-
azetidin-3-yl)methylamino]quinazolin-4(3H)-one (7b). Yield
60% (Acetone): m.p. 173 C; IR (KBr) tmax in cm1: 1759
(C‚O), 1628 (C. . .•C of aromatic ring), 1585 (C‚N), 1317
(C–N), 727 (C–Cl); 1H NMR (CDCl3) d in ppm: 8.34 (s, 1H,
NH exchangeable with D2O), 6.64–7.75 (m, 8H, Ar-H), 5.75
(s, 1H, CH-Ar), 6.48 (d, 1H, J= 6.4 Hz, CHCl), 3.78 (d,
2H, J= 9.2 Hz, CH2NH), 1.12 (m, 15H, amantadinyl ring).
MS: [M]+ at m/z 523.45. Anal. Calc. for C28H28Cl2N4O2: C,
64.25; H, 5.39; N, 10.70. Found: C, 64.22; H, 5.35; N, 10.73%.
6.1.7.3. 3-Amantadinyl-2-[(2-bromophenyl)-3-chloro-2-oxo-
azetidin-3-yl)methylamino]quinazolin-4(3H)-one (7c). Yield
61% (Methanol): m.p. 169 C; IR (KBr) tmax in cm1: 1762
(C‚O), 1630 (C. . .•C of aromatic ring), 1583 (C‚N), 1315
(C–N), 721 (C–Cl), 616 (C–Br); 1H NMR (CDCl3) d in ppm:
8.31 (s, 1H, NH exchangeable with D2O), 6.62–7.72 (m, 8H,
Ar-H), 5.78 (s, 1H, CH-Ar), 6.45 (d, 1H, J= 6.5 Hz, CHCl),
3.75 (d, 2H, J= 9.1 Hz, CH2NH), 1.22 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 567.90. Anal. Calc. for
C28H28BrClN4O2: C, 59.22; H, 4.97; N, 9.87. Found: C,
51.22; H, 4.95; N, 8.85%.
6.1.7.4. 3-Amantadinyl-2-[((2-methoxphenyl)-3-chloro-2-oxo-
azetidin-3-yl)methylamino]quinazolin-4(3H)-one (7d). Yield
64% (Methanol): m.p. 165 C; IR (KBr) tmax in cm1: 1767
(C‚O), 1622 (C. . .•C of aromatic ring), 1587 (C‚N), 1305
(C–N), 1233 (OCH3), 728 (C–Cl);
1H NMR (CDCl3) d in
ppm: 8.40 (s, 1H, NH exchangeable with D2O), 6.62–7.73
(m, 8H, Ar-H), 5.98 (s, 1H, CH-Ar), 6.45 (d, 1H,
J= 6.5 Hz, CHCl), 3.74 (d, 2H, J= 9.1 Hz, CH2NH), 3.21
(s, 3H, OCH3), 1.13 (m, 15H, amantadinyl ring). MS: [M]
+
at m/z 519.03. Anal. Calc. for C29H31ClN4O3: C, 67.11; H,
6.02; N, 10.79. Found: C, 66.15; H, 6.05; N, 10.75%.
6.1.7.5. 3-Amantadinyl-2-[((4-hydroxy3-methoxyphenyl)-3-
chloro-2-oxo-azetidin-3-yl)methylamino]quinazolin-4(3H)-one
(7e). Yield 59% (DMF): m.p. 161 C; IR (KBr) tmax in cm1:
3422 (OH), 1765 (C‚O), 1624 (C. . .•C of aromatic ring), 1583
(C‚N), 1315 (C–N), 1225 (OCH3), 728 (C–Cl);
1H NMR
(CDCl3) d in ppm: 11.13 (s, 1H, OH exchangeable with
D2O), 8.38 (s, 1H, NH exchangeable with D2O), 6.58–7.61
(m, 7H, Ar-H), 5.79 (s, 1H, CH-Ar), 6.41 (d, 1H,
J= 6.4 Hz, CHCl), 3.71 (d, 2H, J= 9.0 Hz, CH2NH), 3.25
(s, 3H, OCH3), 1.16 (m, 15H, amantadinyl ring). MS: [M]
+
at m/z 535.03. Anal. Calc. for C29H31ClN4O4: C, 65.10; H,
5.84; N, 10.47. Found: C, 64.13; H, 5.85; N, 10.55%.
6.1.7.6. 3-Amantadinyl-2[((phenyl)-3-chloro-2-oxo-azetidin-3-
yl)methylamino]-quinazolin-4(3H)-one (7f). Yield 57% (Eth-
484 S. Kumar et al.anol): m.p. 163 C; IR (KBr) tmax in cm1: 1762 (C‚O), 1625
(C. . .•C of aromatic ring), 1584 (C‚N), 1318 (C–N), 726 (C–
Cl); 1H NMR (CDCl3) d in ppm: 8.35 (s, 1H, NH exchange-
able with D2O), 6.62–7.56 (m, 9H, Ar-H), 5.83 (s, 1H, CH-
Ar), 6.46 (d, 1H, J= 6.5 Hz, CHCl), 3.69 (d, 2H,
J= 9.1 Hz, CH2NH), 1.15 (m, 15H, amantadinyl ring). MS:
[M]+ at m/z 489.01. Anal. Calc. for C28H29ClN4O2: C, 78.77;
H, 5.98; N, 11.46. Found: C, 78.69; H, 5.86; N, 11.52%.
6.1.7.7. 3-Amantadinyl-6-bromo-2-[((3,4-dimethoxyphenyl)-3-
chloro-2-oxo–azetidin-3-yl)methylamino]-quinazolin-4(3H)-
one (7g). Yield 55% (Methanol): m.p. 159 C; IR (KBr) tmax
in cm1: 1726 (C‚O), 1635 (C. . .•C of aromatic ring), 1575
(C‚N), 1323 (C–N), 1226 (OCH3), 728 (C–Cl), 627 (C–Br);
1H NMR (CDCl3) d in ppm: 8.44 (s, 1H, NH exchangeable
with D2O), 6.42–7.46 (m, 6H, Ar-H), 5.77 (s, 1H, CH-Ar),
6.43 (d, 1H, J= 6.5 Hz, CHCl), 3.73 (d, 2H, J= 9.1 Hz,
CH2NH), 3.32 (s, 6H, 2 · OCH3), 1.32 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 627.96. Anal. Calc. for
C30H32BrClN4O4: C, 57.38; H, 5.14; N, 8.92. Found: C,
57.35; H, 5.15; N, 8.91%.
6.1.7.8. 3-Amantadinyl-6-bromo-2-[((2-chlorophenyl)-3-
chloro-2-oxo-azetidin-3-yl)methylamino]-quinazolin-4(3H)-
one (7h). Yield 54% (Acetone): m.p. 155 C; IR (KBr) tmax in
cm1: 1723 (C‚O), 1614 (C. . .•C of aromatic ring), 1582
(C‚N), 1316 (C–N), 725 (C–Cl), 623 (C–Br); 1H NMR
(CDCl3) d in ppm: 8.38 (s, 1H, NH exchangeable with D2O),
6.65–7.46 (m, 7H, Ar-H), 5.80 (s, 1H, CH-Ar), 3.72 (d, 2H,
J= 9.1 Hz, CH2NH), 6.45 (d, 1H, J= 6.5 Hz, CHCl), 1.19
(m, 15H, amantadinyl ring). MS: [M]+ at m/z 602.35. Anal.
Calc. for C28H27BrCl2N4O2: C, 55.83; H, 4.52; N, 9.30. Found:
C, 51.82; H, 4.55; N, 8.31%.
6.1.7.9. 3-Amantadinyl-6-bromo-2-[(2-bromophenyl)-3-chloro-
2-oxo-azetidin-3-ylmethylamino]-quinazolin-4(3H)-one (7i).
Yield 58% (Ethanol): m.p. 149 C; IR (KBr) tmax in cm1:
1766 (C‚O), 1627 (C. . .•C of aromatic ring), 1582 (C‚N),
1312 (C–N), 728 (C–Cl), 614 (C–Br); 1H NMR (CDCl3) d in
ppm: 8.37 (s, 1H, NH exchangeable with D2O), 6.67–7.69
(m, 7H, Ar-H), 5.79 (s, 1H, CH-Ar), 3.68 (d, 2H,
J= 9.2 Hz, CH2NH), 6.48 (d, 1H, J= 6.4 Hz, CHCl), 1.18
(m, 15H, amantadinyl ring). MS: [M]+ at m/z 646.80. Anal.
Calc. for C28H27Br2ClN4O2: C, 51.99; H, 4.21; N, 8.66. Found:
C, 51.92; H, 4.25; N, 8.65%.
6.1.7.10. 3-Amantadinyl-6-bromo-2-[((2-methoxyphenyl)-3–
chloro-2-oxo-azetidin-3-yl)methylamino]-quinazolin-4(3H)-one
(7j). Yield 54% (DMF): m.p. 152 C; IR (KBr) tmax in cm1:
1761 (C‚O), 1626 (C. . .•C of aromatic ring), 1583 (C‚N),
1314 (C–N), 1228 (OCH3), 727 (C–Cl), 618 (C–Br);
1H
NMR (CDCl3) d in ppm: 8.36 (s, 1H, NH exchangeable with
D2O), 6.62–7.79 (m, 7H, Ar-H), 5.81 (s, 1H, CH-Ar), 6.52
(d, 1H, J= 6.5 Hz, CHCl), 3.72 (d, 2H, J= 9.1 Hz, CH2NH),
3.39 (s, 3H, OCH3), 1.21 (m, 15H, amantadinyl ring). MS:[M]+ at m/z 597.93. Anal. Calc. for C29H30BrClN4O3: C,
58.25; H, 5.06; N, 9.37. Found: C, 58.22; H, 5.13; N, 9.39%.
6.1.7.11. 3-Amantadinyl-6-bromo-2-[((4-hydroxy3-methoxy-
phenyl)-3-chloro-2-oxo-azetidin-3-yl)methylamino]-quinazolin-
4(3H)-one (7k). Yield 51% (Ethanol): m.p. 147 C; IR (KBr)
tmax in cm
1: 3432 (OH), 1765 (C‚O), 1626 (C. . .•C of aro-
matic ring), 1580 (C‚N), 1310 (C–N), 1234 (OCH3), 726
(C–Cl), 614 (C–Br); 1H NMR (CDCl3) d in ppm: 11.20
(s, 1H, OH exchangeable with D2O), 8.37 (s, 1H, NH
exchangeable with D2O), 6.71–7.72 (m, 6H, Ar-H), 5.78 (s,
1H, CH-Ar), 6.43 (d, 1H, J= 6.5 Hz, CHCl), 3.73 (d, 2H,
J= 9.1 Hz, CH2NH), 3.41 (s, 3H, OCH3), 1.27 (m, 15H,
amantadinyl ring). MS: [M]+ at m/z 613.93. Anal. Calc. for
C29H30BrClN4O4: C, 56.73; H, 4.93; N, 9.13. Found: C,
56.72; H, 4.95; N, 9.23%.
6.1.7.12. 3-Amantadinyl-6-bromo-2-[((phenyl)3-chloro-2-oxo-
azetidin-3-yl)methylamino]-quinazolin-4(3H)-one (7l). Yield
56% (Methanol): m.p. 152 C; IR (KBr) tmax in cm1: 1765
(C‚O), 1623 (C. . .•C of aromatic ring), 1585 (C‚N), 1315
(C–N), 725 (C–Cl), 624 (C–Br); 1H NMR (CDCl3) d in ppm:
8.34 (s, 1H, NH exchangeable with D2O), 6.69–7.73 (m, 8H,
Ar-H), 5.81 (s, 1H, CH-Ar), 6.42 (d, 1H, J= 6.5 Hz, CHCl),
3.71 (d, 2H, J= 9.2 Hz, CH2NH), 1.27 (m, 15H, amantadinyl
ring). MS: [M]+ at m/z 567.90. Anal. Calc. for
C28H28BrClN4O2: C, 59.22; H, 4.97; N, 9.87. Found: C,
59.25; H, 4.95; N, 9.88%.
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